Abstract
Testosterone deficiency syndrome (TDS) induces several negative effects that generally involve different organs such as testis, bone, skeletal muscle, and heart, leading to reduction in testis function, causing osteoporosis, strongly reducing muscle mass, decreasing exercise capacity and strength and facilitating heart failure. Approximately 25% of patients affected by chronic heart failure (CHF) is characterized by plasma Testosterone (T) levels below normal ranges also related to disease progression. In addition, reduction of circulating testosterone levels may contribute to some specific features of CHF, such as abnormal energy handling, weakness, dyspnoea and cachexia in particular. According to some recent evidence it has emerged that testosterone replacement therapy (TRT) may improve muscle strength and functional pulmonary capacity in CHF men with TDS.
This review will place emphasis on the pathophysiological role of testosterone deficiency in CHF men as well as the effects of the testosterone replacement therapy.
Keywords: Heart failure, hypogonadism, testosterone deficiency, testosterone replacement therapy.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Volume: 13 Issue: 1
Author(s): Vito Angelo Giagulli, Edoardo Guastamacchia, Giovanni De Pergola, Massimo Iacoviello and Vincenzo Triggiani
Affiliation:
Keywords: Heart failure, hypogonadism, testosterone deficiency, testosterone replacement therapy.
Abstract: Testosterone deficiency syndrome (TDS) induces several negative effects that generally involve different organs such as testis, bone, skeletal muscle, and heart, leading to reduction in testis function, causing osteoporosis, strongly reducing muscle mass, decreasing exercise capacity and strength and facilitating heart failure. Approximately 25% of patients affected by chronic heart failure (CHF) is characterized by plasma Testosterone (T) levels below normal ranges also related to disease progression. In addition, reduction of circulating testosterone levels may contribute to some specific features of CHF, such as abnormal energy handling, weakness, dyspnoea and cachexia in particular. According to some recent evidence it has emerged that testosterone replacement therapy (TRT) may improve muscle strength and functional pulmonary capacity in CHF men with TDS.
This review will place emphasis on the pathophysiological role of testosterone deficiency in CHF men as well as the effects of the testosterone replacement therapy.
Export Options
About this article
Cite this article as:
Giagulli Vito Angelo, Guastamacchia Edoardo, Pergola Giovanni De, Iacoviello Massimo and Triggiani Vincenzo, Testosterone Deficiency in Male: A Risk Factor for Heart Failure, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010011
DOI https://dx.doi.org/10.2174/1871530311313010011 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacologic Targeting of Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs)
Current Vascular Pharmacology Endothelial Dysfunction in Renal Failure: Current Update
Current Medicinal Chemistry The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease
Current Medicinal Chemistry Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design Non-pharmacological Strategies Against Systemic Inflammation: Molecular Basis and Clinical Evidence
Current Pharmaceutical Design Weight Loss in Older Persons: New Therapeutic Approaches
Current Pharmaceutical Design Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Current Drug Metabolism Preface
Current Cardiology Reviews Synthesis and In Vitro Evaluation of Some Isatin-Thiazolidinone Hybrid Analogues as Anti-Proliferative Agents
Medicinal Chemistry Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) Coronary Artery Disease and End-Stage Renal Disease - A Clinical Perspective
Current Hypertension Reviews Bio-Active Chemical Constituents from the Genus Streptocaulon
Mini-Reviews in Organic Chemistry Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome
Current Bioactive Compounds Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
Current Drug Metabolism